NVDA
NVIDIA Corporation
NVDA has the edge over ZENA overall, supported by stronger valuation and stronger fundamentals.
ZENA
ZenaTech, Inc.
ZENA's outlook is improving, though it still trails on the overall score.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
ZENA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Weak |
ZENA's revenue is currently healthy, but its profitability, cash flow and balance sheet are weak.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
ZENA PE Valuation
ZENA has no meaningful PE right now: it lost money over the past year.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
ZENA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect ZENA's losses to shrink, with revenue growing.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over ZENA on earnings quality, reporting a profit while its opponent remains loss making.
ZENA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.41 | -$1.00 |
| Q1 2026 | -$1.34 | -$1.05 |
| Q4 2025 | -$0.93 | -$0.78 |
| Q3 2025 | -$0.62 | -$0.58 |
| Q2 2025 | -$0.41 | -$0.39 |
| Q1 2025 | -$0.29 | -$0.28 |
| Q4 2024 | -$0.15 | -$0.14 |
| Q3 2024 | -$0.04 | -$0.02 |
ZENA lost $1.41 per share over the past year, and its loss has widened in each of the last nine quarters.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA's revenue has grown year over year for 13 quarters in a row: $96.2B last quarter, up 106% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over ZENA on profitability, with a higher operating margin.
ZENA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $6.5M | +314% |
| Q1 2026 | $6M | +652% |
| Q4 2025 | $3.6M | +671% |
| Q3 2025 | $3.1M | +1225% |
| Q2 2025 | $1.6M | +504% |
| Q1 2025 | $798.4K | +92% |
| Q4 2024 | $473.4K | -4.4% |
| Q3 2024 | $230.5K | +23% |
ZENA's revenue has grown year over year for six quarters in a row: $7M last quarter, up 314% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -235% | -60 points |
| Q1 2026 | -257% | +6.8 points |
| Q4 2025 | -262% | +97 points |
| Q3 2025 | -101% | +61 points |
| Q2 2025 | -174% | -149 points |
| Q1 2025 | -263% | -269 points |
| Q4 2024 | -359% | -420 points |
| Q3 2024 | -162% | -131 points |
ZENA's operating margin was −235% last quarter, down 60 points from the same quarter a year ago.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over ZENA on cash generation, producing positive trailing cash flow while its opponent burns cash.
ZENA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$18.9M | -$13.7M |
| Q1 2026 | -$14.9M | -$10.9M |
| Q4 2025 | -$14.2M | -$10M |
| Q3 2025 | -$5.9M | -$4.3M |
| Q2 2025 | -$5.2M | -$4.9M |
| Q1 2025 | -$4M | -$3.7M |
| Q4 2024 | -$4.2M | -$2.8M |
| Q3 2024 | -$1.6M | -679% |
ZENA has burned cash in almost every quarter: −$54M over the past year, against −$15M the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over ZENA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
ZENA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +137% | +46.8M shares |
| 1 year | +156% | +49.3M shares |
| 3 years | +381% | +64.1M shares |
ZENA has 81M diluted shares, up 156% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ZENA hasn't bought back shares in the past year.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
ZENA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | 81.3x | High |
| Q2 2024 | 17.6x | High |
| Q1 2024 | 16.8x | High |
| Q4 2023 | 17.2x | High |
| Q3 2023 | 46.4x | High |
| Q2 2023 | 17.0x | High |
| Q1 2023 | 0.0x | Very low |
| Q4 2022 | 8.4x | High |
ZENA's net debt is more than 20 years of its operating earnings (EBITDA), up from more than 20 years a year ago.
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
ZENA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.3 | Oversold |
| Stochastic | 2.7 | Oversold |
ZENA's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
ZENA PE vs Technology Sector
ZENA has no meaningful PE right now: it lost money over the past year.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has stronger trend alignment. NVDA is above 1 of 5 weekly averages versus ZENA above 0 of 4.
ZENA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.01 | 38% below |
| 20 week MA | $1.36 | 54% below |
| 50 week MA | $2.06 | 69% below |
| 100 week MA | $3.23 | 80% below |
ZENA is in a downtrend: it's below all four of its weekly moving averages, and 80% below its 100-week average.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over ZENA on returns for 2026, with the stronger performance.
ZENA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $3.91 | $8.48 | +117% |
| 2025 | $8.48 | $3.42 | -60% |
| 2026 YTD | $3.42 | $0.63 | -82% |
ZENA's yearly returns have swung widely, from +117% in 2024 to −60% in 2025. It's down 82% so far in 2026.